Virax Biolabs Group (VRAX) Competitors $0.96 +0.04 (+4.41%) Closing price 03:53 PM EasternExtended Trading$0.95 -0.01 (-1.42%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRAX vs. MTEX, EDSA, FLGC, ATHA, ALLR, PMN, SNPX, LEXX, NEUP, and HOOKShould you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Mannatech (MTEX), Edesa Biotech (EDSA), Flora Growth (FLGC), Athira Pharma (ATHA), Allarity Therapeutics (ALLR), Promis Neurosciences (PMN), Synaptogenix (SNPX), Lexaria Bioscience (LEXX), Neuphoria Therapeutics (NEUP), and HOOKIPA Pharma (HOOK). These companies are all part of the "pharmaceutical products" industry. Virax Biolabs Group vs. Its Competitors Mannatech Edesa Biotech Flora Growth Athira Pharma Allarity Therapeutics Promis Neurosciences Synaptogenix Lexaria Bioscience Neuphoria Therapeutics HOOKIPA Pharma Mannatech (NASDAQ:MTEX) and Virax Biolabs Group (NASDAQ:VRAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership. Which has higher valuation and earnings, MTEX or VRAX? Mannatech has higher revenue and earnings than Virax Biolabs Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMannatech$117.87M0.13$2.49M-$0.10-78.30Virax Biolabs Group$10K416.90-$6.06MN/AN/A Which has more risk & volatility, MTEX or VRAX? Mannatech has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Virax Biolabs Group has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Do analysts rate MTEX or VRAX? Virax Biolabs Group has a consensus target price of $3.00, indicating a potential upside of 212.30%. Given Virax Biolabs Group's stronger consensus rating and higher probable upside, analysts clearly believe Virax Biolabs Group is more favorable than Mannatech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mannatech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Virax Biolabs Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in MTEX or VRAX? 13.0% of Mannatech shares are owned by institutional investors. Comparatively, 8.6% of Virax Biolabs Group shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Comparatively, 45.1% of Virax Biolabs Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media favor MTEX or VRAX? In the previous week, Virax Biolabs Group had 1 more articles in the media than Mannatech. MarketBeat recorded 1 mentions for Virax Biolabs Group and 0 mentions for Mannatech. Virax Biolabs Group's average media sentiment score of 1.89 beat Mannatech's score of 1.87 indicating that Virax Biolabs Group is being referred to more favorably in the news media. Company Overall Sentiment Mannatech Very Positive Virax Biolabs Group Very Positive Is MTEX or VRAX more profitable? Virax Biolabs Group has a net margin of 0.00% compared to Mannatech's net margin of -0.19%. Virax Biolabs Group's return on equity of 0.00% beat Mannatech's return on equity.Company Net Margins Return on Equity Return on Assets Mannatech-0.19% -2.56% -0.57% Virax Biolabs Group N/A N/A N/A SummaryVirax Biolabs Group beats Mannatech on 11 of the 14 factors compared between the two stocks. Get Virax Biolabs Group News Delivered to You Automatically Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRAX vs. The Competition Export to ExcelMetricVirax Biolabs GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.17M$2.91B$5.52B$9.41BDividend YieldN/A2.45%3.80%4.04%P/E RatioN/A19.8828.0419.84Price / Sales416.90305.11429.5399.59Price / CashN/A43.1635.8457.94Price / Book0.767.678.125.65Net Income-$6.06M-$55.28M$3.25B$258.00M7 Day Performance6.73%2.50%0.97%2.09%1 Month Performance18.45%11.70%7.36%11.13%1 Year Performance-16.47%4.89%31.31%18.40% Virax Biolabs Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRAXVirax Biolabs Group3.1336 of 5 stars$0.96+4.4%$3.00+212.3%-25.2%$3.99M$10K0.005News CoveragePositive NewsGap UpMTEXMannatech1.227 of 5 stars$8.20-3.5%N/A+12.3%$15.58M$117.87M-81.99250Positive NewsEDSAEdesa Biotech2.2088 of 5 stars$2.19-0.6%$5.00+128.7%-49.5%$15.37MN/A-1.3820Positive NewsGap UpFLGCFlora Growth2.5108 of 5 stars$0.68-1.9%$4.00+491.7%-42.6%$15.35M$53.26M-0.69280Positive NewsATHAAthira Pharma3.7754 of 5 stars$0.39-2.3%$11.25+2,762.6%-88.4%$15.34MN/A-0.1940Positive NewsGap UpALLRAllarity Therapeutics0.6576 of 5 stars$1.01-3.8%N/A-83.7%$15.16MN/A0.0010Positive NewsPMNPromis Neurosciences3.1605 of 5 stars$0.45-14.4%$4.33+873.8%-78.1%$14.61MN/A-8.945News CoverageAnalyst RevisionGap UpHigh Trading VolumeSNPXSynaptogenix0.2484 of 5 stars$10.38+15.5%N/A+107.8%$14.43MN/A-1.034Positive NewsGap UpHigh Trading VolumeLEXXLexaria Bioscience1.9581 of 5 stars$0.81-2.4%$5.00+514.3%-69.8%$14.29M$460K-1.387Earnings ReportNEUPNeuphoria Therapeutics1.8924 of 5 stars$7.58-1.6%$21.00+177.0%N/A$14.25M$15.66M0.00N/ANews CoveragePositive NewsHOOKHOOKIPA Pharma3.2316 of 5 stars$1.17-2.9%$4.50+286.3%-82.4%$14.20M$43.95M-0.20160News CoveragePositive NewsTrading Halted Related Companies and Tools Related Companies Mannatech Competitors Edesa Biotech Competitors Flora Growth Competitors Athira Pharma Competitors Allarity Therapeutics Competitors Promis Neurosciences Competitors Synaptogenix Competitors Lexaria Bioscience Competitors Neuphoria Therapeutics Competitors HOOKIPA Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRAX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
